Found and Sequence are both legitimate GLP-1 telehealth platforms but they serve different patient profiles and sit at meaningfully different price points. Found is a mid-range behavioral platform ($129–$249/mo for semaglutide) with app-based coaching bundled in. Sequence is a premium clinical model ($249–$399/mo for semaglutide) centered on dedicated provider teams and intensive medical oversight. Both use dose-dependent pricing that increases as patients reach maintenance doses.
For patients whose primary goal is cost-effective, pharmacy-transparent, no-contract GLP-1 treatment, Luma Health offers compounded semaglutide at $197/month flat and tirzepatide at $297/month flat — below both Found and Sequence at maintenance doses, with no price increases, no contracts, and a publicly verifiable pharmacy (VialsRX, TX Board #35264).
- 📈 Dose-tier pricing — rises with escalation
- 📱 App-based behavioral coaching
- 👥 Community + habit tracking
- ⚠️ Contract terms vary by plan
- 🚚 Free shipping on most plans
- 📈 Dose-tier pricing — premium at all tiers
- 👩⚕️ Dedicated provider teams
- 🏥️ Insurance coordination available
- ⚠️ Multi-month commitments common
- 🚚 Shipping varies by plan
- ✅ No dose-tier increases — ever
- ✅ No contracts — month-to-month
- ✅ VialsRX pharmacy, TX Board #35264
- ✅ Wasef Health, PC — clinical provider
- ✅ Free shipping — all 50 states
What Found and Sequence Have in Common
Before examining the differences, it is worth being clear about what Found and Sequence share — because on the most clinically important dimension, they are identical. Both platforms prescribe compounded semaglutide and tirzepatide. The active pharmaceutical ingredient is the same regardless of which platform issues the prescription. The GLP-1 receptor agonism that semaglutide produces — suppressing appetite through hypothalamic pathways, slowing gastric emptying, and improving satiety signaling — occurs identically whether the prescription comes from Found, Sequence, or any other properly licensed telehealth provider using a legitimate 503A compounding pharmacy.
This matters because it defines the ceiling on how much the surrounding program structure — the app, the coaching model, the provider team configuration — can affect clinical outcomes. The medication produces the weight loss documented in the STEP 1 and SURMOUNT-1 trials. The platform determines how you access, afford, and are supported through that medication. Platform differences are real and worth evaluating, but they should not be mistaken for differences in the underlying pharmacology.
Both platforms also operate primarily as cash-pay telehealth services. Both use US-licensed prescribers. Both require a clinical intake before prescribing. Both ship medication directly to patients. And both — this is the key pricing commonality — use dose-dependent pricing that increases as patients move from starting doses to therapeutic maintenance doses. This means neither platform's advertised starting price reflects what patients actually pay during the majority of their treatment course.
The Clinical Evidence Both Platforms Build On
The weight loss outcomes patients can realistically expect from GLP-1 treatment are established by large-scale randomized controlled trial data, not by any platform's marketing claims. The STEP 1 trial (Wilding et al., NEJM, 2021) enrolled 1,961 adults with obesity and demonstrated a mean body weight reduction of 14.9% at 68 weeks with semaglutide 2.4 mg weekly — approximately one-third of participants lost 20% or more of their body weight. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) demonstrated mean body weight reductions of 15.0%, 19.5%, and 20.9% at tirzepatide doses of 5 mg, 10 mg, and 15 mg weekly over 72 weeks.
Neither Found nor Sequence has published independent comparative data showing that their specific platform model produces superior outcomes to these trial benchmarks or to competitors offering the same medications. The pharmacology is what drives outcomes. The platform determines whether you can afford to stay on treatment long enough to achieve them.
Found: The Behavioral Mid-Tier Platform
Found was built on the premise that GLP-1 medication works best when paired with behavioral intervention. The platform invests heavily in its app infrastructure — meal tracking, habit coaching modules, community forums, progress visualization, and educational content on nutrition and lifestyle. For patients who genuinely engage with these tools, Found delivers a genuinely comprehensive program experience that goes beyond simple medication access.
The clinical rationale for Found's model is sound. Research consistently shows that behavioral interventions improve weight loss outcomes when combined with pharmacotherapy. The STEP 4 trial demonstrated that patients who continued semaglutide after initial weight loss maintained their outcomes significantly better than those who switched to placebo — and structured behavioral support alongside medication is associated with improved maintenance in multiple obesity medicine studies. Found's platform is designed to operationalize that behavioral support at scale through technology.
The limitations of Found's approach are also real. Digital health engagement data consistently shows that app usage drops sharply after the first 60 to 90 days for most users. Patients who were highly engaged in month one often find themselves using the app minimally by month four — but they continue paying the same (or higher) monthly rate that included the behavioral infrastructure. If a patient reaches their maintenance dose at month three and the app becomes background noise by month four, they are effectively paying Found's premium for medication-only access from that point forward.
Found's pricing adds another layer of complexity. The $129/month starting price applies only at the lowest dose tier. As patients titrate upward — which is clinically expected and takes most patients three to five months — the monthly cost increases at each tier to $149–$169, then $179–$199, then $199–$249 at higher maintenance doses. A patient who enrolled based on the $129 starting price and reaches a 1.7 mg maintenance dose may be paying $199–$229 per month by month five — an increase of 54% to 77% from their enrollment price.
Sequence: The Premium Clinical Model
Sequence takes a fundamentally different approach from Found. Rather than investing in consumer-facing technology and behavioral tools, Sequence invests in clinical depth — specifically in dedicated provider teams that follow individual patients throughout their treatment rather than rotating through different providers at each visit. The clinical value proposition is continuity of care: a provider who knows your response history, your side effect patterns, your titration trajectory, and your comorbidities can make better clinical decisions than a provider seeing you for the first time at each interaction.
This model has genuine clinical merit. In obesity medicine, as in most chronic disease management, longitudinal provider relationships are associated with better adherence, more nuanced dose management, and earlier identification of patients who are not responding optimally and may benefit from medication changes. Sequence's dedicated team model replicates the continuity that specialist clinics provide but through a telehealth delivery format.
The trade-off is cost. Sequence is the most expensive widely available GLP-1 telehealth option in the market at $249 to $399 per month for semaglutide — two to three times the price of Luma Health for the same active ingredient. At that price point, the dedicated provider relationship is the primary differentiator, and its value depends entirely on whether your clinical situation genuinely benefits from intensive provider oversight. A patient with straightforward GLP-1 eligibility, no complex comorbidities, and uncomplicated dose escalation may find Sequence's premium clinical infrastructure exceeds what their situation requires. A patient with multiple comorbidities, previous GLP-1 failures, complex medication interactions, or an unusual response pattern may find Sequence's deeper clinical engagement genuinely valuable.
Sequence has also historically offered some insurance coordination for branded GLP-1 medications — an advantage for patients with employer plans that cover Wegovy or Zepbound. However, for the majority of patients seeking compounded GLP-1 access on a cash-pay basis, this feature is less relevant, and the full $249 to $399 monthly price is what they actually pay.
Full Side-by-Side Comparison: Found vs Sequence vs Luma Health
| Factor | Found | Sequence | Luma Health |
|---|---|---|---|
| Sema starting price | ~$129/mo | ~$249/mo | $197/mo |
| Sema at 1.0 mg maintenance | ~$179–$199/mo | ~$299–$349/mo | $197/mo (flat) |
| Sema at 2.4 mg maintenance | ~$229–$249/mo | ~$349–$399/mo | $197/mo (flat) |
| Tirz starting price | ~$199/mo | ~$349/mo | $297/mo |
| Tirz at maintenance | ~$249–$299/mo | ~$349–$399/mo | $297/mo (flat) |
| Est. sema 12-month total | ~$1,900–$2,700+ | ~$3,000–$4,800+ | $2,364 (flat) |
| Dose-tier price increases | Yes — rises with dose | Yes — rises with dose | ✓ None — always flat |
| Contract terms | Varies by plan | Multi-month common | ✓ None — month-to-month |
| Behavioral coaching app | ✓ Yes — full app | Limited | Clinical support only |
| Dedicated provider team | Rotating providers | ✓ Yes — dedicated team | Wasef Health, PC |
| Insurance coordination | Limited | Some branded coverage | Cash-pay (no insurance needed) |
| Pharmacy publicly named | ✗ Not prominently | ✗ Not prominently | ✓ VialsRX, TX #35264 |
| Shipping | Free–$9.99/mo | Varies | ✓ Always free |
| All 50 states | Most states | Most states | ✓ All 50 states |
Pricing at Maintenance Dose: Where the Real Comparison Lives
The most important pricing comparison between Found, Sequence, and Luma Health is not at the starting dose — it is at the maintenance dose where patients spend the majority of their treatment time. The standard semaglutide titration protocol takes approximately three to five months to reach a therapeutic maintenance dose of 1.0 mg to 2.4 mg weekly. From that point, most clinical guidelines recommend remaining on treatment for at least 12 to 18 months to achieve and consolidate meaningful outcomes. This means patients spend roughly two to four months at starting and intermediate doses and eight to ten months at or near maintenance.
At those maintenance doses, the pricing picture changes substantially. Found at 2.4 mg maintenance costs approximately $229 to $249 per month — $32 to $52 more than Luma Health's flat $197. Sequence at 2.4 mg maintenance costs approximately $349 to $399 per month — $152 to $202 more per month than Luma Health. Over the eight to ten months that most patients spend at maintenance, that differential accumulates to $256 to $520 in savings versus Found and $1,216 to $2,020 in savings versus Sequence by choosing Luma Health.
Clinical Philosophy: Behavioral vs. Clinical Depth vs. Cost Efficiency
Coaching Model Found
Found invests in behavioral tools — habit tracking, meal guidance, community forums, educational modules — delivered through the Found app. This model reflects a genuine clinical philosophy: that medication works best alongside structured behavioral support. The limitation is engagement drop-off: most digital health tools see substantial usage decline after 60 to 90 days, meaning the behavioral infrastructure may be actively used only in the first phase of treatment for many patients.
Provider Model Sequence
Sequence's dedicated provider team model delivers clinical depth that rotating-provider platforms cannot match. Providers who follow a patient longitudinally accumulate knowledge about their response patterns, side effect history, and titration trajectory — enabling more nuanced dose management decisions. This is most valuable for patients with complex clinical profiles; for straightforward GLP-1 cases, the dedicated team model may represent clinical infrastructure the patient does not need to pay for.
Cost Structure Luma Health
Luma Health's flat-rate model eliminates the primary source of GLP-1 pricing surprises: dose-dependent increases. The same $197/month rate applies whether a patient is at 0.25 mg or 2.4 mg weekly — making long-term budget planning straightforward and removing the incentive for providers to delay dose escalation for cost reasons. For patients whose priority is predictable, affordable, pharmacy-transparent GLP-1 access, flat-rate pricing is the most patient-aligned structure in the market.
Pharmacy Transparency Luma Health
Neither Found nor Sequence prominently discloses the name and license number of the compounding pharmacies that prepare their medications on their consumer-facing websites. Luma Health uses VialsRX, a 503A licensed sterile compounding pharmacy in Houston, TX (Texas State Board of Pharmacy license #35264, verifiable at pharmacy.texas.gov). For patients who want to independently verify the pharmacy preparing their injectable medication, this distinction matters.
Who Each Provider Is Best For
The right choice between Found, Sequence, and Luma Health depends on what you are actually trying to optimize for in a GLP-1 program. These platforms serve meaningfully different patient profiles, and understanding which profile matches your situation is more useful than a generic "which is better" verdict.
Found is the best fit for patients who actively engage with behavioral health tools and want app-based structure alongside their medication. If you know from prior experience that habit tracking, meal logging, community accountability, and guided behavioral modules help you maintain lifestyle changes, Found's bundled model delivers real value for that engagement. Found is also a reasonable mid-range choice for patients who want more than bare-bones clinical access but are not willing to pay Sequence's premium prices. The main caveat is to ask for the full dose-tier pricing schedule upfront and budget for maintenance-dose costs, not just the starting rate.
Sequence is the best fit for patients with genuinely complex clinical profiles — multiple comorbidities, previous GLP-1 treatment failures, complex medication interactions, or unusual metabolic responses that benefit from sustained, sophisticated clinical management. The dedicated provider team model's clinical depth is a real differentiator for these patients. Sequence is also worth evaluating for patients whose employer health insurance covers branded GLP-1 medications, since Sequence offers some insurance coordination that compounded-only platforms do not. For straightforward GLP-1 cases, Sequence's premium is difficult to justify against alternatives at half the price.
Luma Health is the best fit for patients whose primary goals are cost predictability, pharmacy transparency, and no-contract flexibility — particularly those who are at or approaching a maintenance dose and want to avoid the escalating costs that both Found and Sequence build into their pricing structures. Patients currently on Found or Sequence who have stabilized at a maintenance dose and find the behavioral or clinical add-ons underutilized should evaluate whether switching to Luma Health's flat-rate model represents meaningful annual savings without clinical trade-off.
Frequently Asked Questions
Is Found or Sequence better for GLP-1 weight loss?
It depends on your specific priorities. Found is the stronger choice for patients who will actively use app-based behavioral coaching tools, community features, and habit tracking — the behavioral infrastructure Found has built is well-designed and reflects genuine clinical rationale. Sequence is the stronger choice for patients with complex clinical profiles who benefit from dedicated provider continuity and more intensive ongoing medical oversight. For patients whose priority is cost-effective, pharmacy-transparent GLP-1 access without contracts, Luma Health's flat-rate model is competitive with Found at starting doses and less expensive than both Found and Sequence at maintenance doses.
How much does Found semaglutide cost vs Sequence in 2026?
Found's semaglutide pricing ranges from approximately $129/month at the starting dose to $229–$249/month at the 2.4 mg maintenance dose. Sequence's semaglutide pricing ranges from approximately $249/month at starting tiers to $349–$399/month at maintenance. Over a 12-month course that includes both the titration phase and several months at maintenance, Found typically costs $1,900 to $2,700 and Sequence typically costs $3,000 to $4,800. Luma Health's flat $197/month totals $2,364 annually regardless of dose — below Found's maintenance pricing and substantially below Sequence's across the full treatment course.
Do Found and Sequence use the same compounded semaglutide?
Both Found and Sequence prescribe compounded semaglutide prepared by licensed 503A sterile compounding pharmacies. The active pharmaceutical ingredient — semaglutide — is the same molecule at the same concentrations regardless of which platform issues the prescription. The pharmacology is identical: GLP-1 receptor agonism through the same mechanism that produced the 14.9% body weight reduction documented in the STEP 1 trial. Differences between Found and Sequence are differences in program structure, pricing, and clinical support model — not in the medication itself.
Does Sequence's dedicated provider team produce better outcomes?
Sequence's dedicated provider team model delivers genuine clinical value — specifically for patients whose cases benefit from longitudinal provider knowledge. Providers who follow a patient through the full titration and maintenance course can make more nuanced dose adjustment decisions and identify non-response patterns more quickly than providers seeing a patient for the first time at each visit. However, no published data demonstrates that Sequence's specific platform produces superior weight loss outcomes compared to other properly managed GLP-1 programs. The medication's pharmacology — not the platform model — is the primary driver of clinical outcomes in uncomplicated cases. For complex cases, the dedicated team model's value is more clinically meaningful.
Are Found and Sequence the same medication as Wegovy?
Both Found and Sequence prescribe compounded semaglutide, which contains the same active pharmaceutical ingredient as brand-name Wegovy. Compounded semaglutide is not an FDA-approved drug product in the way Wegovy is — it is prepared per individual prescription by licensed 503A compounding pharmacies under state pharmacy board oversight. When prepared by a properly licensed pharmacy following USP chapter 797 sterile compounding standards, the active ingredient is pharmacologically equivalent to the branded version and produces the same GLP-1 receptor agonist effects at the same doses.
Can I switch from Found or Sequence to Luma Health mid-treatment?
Yes. Switching does not require restarting the titration protocol. Your Luma Health clinical provider will prescribe at your current dose based on your treatment history. The process takes two to five business days for intake review and prescription approval, plus three to seven days for medication shipping. The most important step is to complete your Luma Health intake and confirm prescription approval before canceling your current provider — not simultaneously or after. This ensures you have continuous medication supply with no gap at your current dose level.
Does Found's behavioral coaching actually improve weight loss outcomes?
The clinical evidence for behavioral intervention combined with GLP-1 medication is generally positive — structured behavioral support is associated with improved weight loss outcomes and better maintenance compared to medication alone in multiple studies. However, this evidence refers to behavioral intervention broadly, not to Found's specific app. No published comparative data exists showing that Found's platform specifically produces superior outcomes to a well-managed medication program without app-based coaching. The benefit of Found's behavioral tools depends substantially on individual engagement: patients who actively use the app and find behavioral structure helpful are more likely to see the value; patients who use the app minimally are paying for infrastructure that may not affect their outcomes.
What should I ask Found or Sequence before enrolling?
Before enrolling with either provider, ask: What is the exact monthly cost at each dose tier — starting, intermediate, and maximum maintenance? Are there any additional fees for consultations, shipping, or labs not included in the base monthly rate? What are the contract terms and what does early cancellation cost? What is the name and state pharmacy board license number of the compounding pharmacy that will prepare my medication? Can I independently verify that pharmacy license? What happens to my prescription and my clinical history if I decide to switch providers? Getting clear written answers to these questions before providing payment information is the most important consumer protection step in this market.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414–1425. PubMed
- Wadden TA, et al. Intensive behavioral therapy and liraglutide for obesity. N Engl J Med. 2024. PubMed
- FDA. Wegovy (semaglutide) Prescribing Information. 2023. FDA.gov
- FDA. Zepbound (tirzepatide) Prescribing Information. 2023. FDA.gov
- FDA. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- Garvey WT, et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1–203. Endocrine Practice
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov